Close
4

Quotient Sciences Quotient Sciences

X

Company profile for EMERCell

  • Webinars & Exhibitions

PharmaCompass
About the Company
Related CompaniesRelated Companies
EMERCell is developing a generic cell immunotherapy NK-based to be used in synergy with monoclonal antibodies (MAbs) to treat refractory patients in oncology. This new and innovative drug therapy called NK-001 consists of allogeneic Natural Killer (NK) cells which are produced ex vivo according to a patented process. NK lymphocytes present natural cytotoxicity and specific cytotoxicity in association with MAbs (Antibody-Depen...
EMERCell is developing a generic cell immunotherapy NK-based to be used in synergy with monoclonal antibodies (MAbs) to treat refractory patients in oncology. This new and innovative drug therapy called NK-001 consists of allogeneic Natural Killer (NK) cells which are produced ex vivo according to a patented process. NK lymphocytes present natural cytotoxicity and specific cytotoxicity in association with MAbs (Antibody-Dependent Cell Cytotoxicity (ADCC)) and are known for their natural immunology surveillance of cancers.

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Send me more info on How To Grow My Bussiness Digitally?
EMERCell
France Flag
Country
Country
France
Address
Address
36 Chemin de l’hôpital 34270 St Mathieu de Tréviers
Telephone
Telephone
+(33) 6.14.77.39.21
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY